{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T13:07:40Z","timestamp":1775567260978,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15795-9","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T03:04:34Z","timestamp":1772161474000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tumor-Infiltrating lymphocyte dynamics as biomarkers of neoadjuvant treatment response in luminal breast cancer"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1822-3870","authenticated-orcid":false,"given":"Esma","family":"Uguztemur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8742-5014","authenticated-orcid":false,"given":"Merve","family":"Dogan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"15795_CR1","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/s41523-021-00346-1","volume":"7","author":"K El Bairi","year":"2021","unstructured":"El Bairi K, Haynes HR, Blackley E, et al. The tale of TILs in breast cancer: a report from the International Immuno-Oncology Biomarker Working Group. NPJ Breast Cancer. 2021;7:150. https:\/\/doi.org\/10.1038\/s41523-021-00346-1.","journal-title":"NPJ Breast Cancer"},{"issue":"10","key":"15795_CR2","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.annonc.2021.07.007","volume":"32","author":"S Loi","year":"2021","unstructured":"Loi S, Michiels S, Adams S, et al. The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition. Ann Oncol. 2021;32(10):1236\u201344. https:\/\/doi.org\/10.1016\/j.annonc.2021.07.007.","journal-title":"Ann Oncol"},{"issue":"1","key":"15795_CR3","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-x","volume":"19","author":"C Denkert","year":"2018","unstructured":"Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumor-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients. Lancet Oncol. 2018;19(1):40\u201350. https:\/\/doi.org\/10.1016\/S1470-2045(17)30904-x.","journal-title":"Lancet Oncol"},{"issue":"9938","key":"15795_CR4","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164\u201372. https:\/\/doi.org\/10.1016\/S0140-6736(13)62422-8.","journal-title":"Lancet"},{"issue":"24","key":"15795_CR5","doi-asserted-by":"publisher","first-page":"5427","DOI":"10.1158\/0008-5472.CAN-20-1792","volume":"80","author":"M Huang","year":"2020","unstructured":"Huang M, O\u2019Shaughnessy J, Zhao J, et al. Association of pathologic complete response with long-term survival outcomes in breast cancer: a meta-analysis. Cancer Res. 2020;80(24):5427\u201334. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-1792.","journal-title":"Cancer Res"},{"key":"15795_CR6","doi-asserted-by":"publisher","first-page":"9959","DOI":"10.3390\/ijms26209959","volume":"26","author":"R Kim","year":"2025","unstructured":"Kim R, Kin T, Arihiro K. Roles of tumor-infiltrating lymphocytes and antitumor immune responses as predictive and prognostic markers in patients with breast cancer receiving neoadjuvant chemotherapy. Int J Mol Sci. 2025;26:9959. https:\/\/doi.org\/10.3390\/ijms26209959.","journal-title":"Int J Mol Sci"},{"issue":"49","key":"15795_CR7","doi-asserted-by":"publisher","first-page":"e40845","DOI":"10.1097\/MD.0000000000040845","volume":"103","author":"EI Obeagu","year":"2024","unstructured":"Obeagu EI, Obeagu GU. Lymphocyte infiltration in breast cancer: a promising prognostic indicator. Med (Baltim). 2024;103(49):e40845. https:\/\/doi.org\/10.1097\/MD.0000000000040845.","journal-title":"Med (Baltim)"},{"key":"15795_CR8","doi-asserted-by":"publisher","first-page":"674192","DOI":"10.3389\/fimmu.2021.674192","volume":"12","author":"J Goldberg","year":"2021","unstructured":"Goldberg J, Pastorello R, Vallius T, et al. Immunology of HR+ breast cancer. Front Immunol. 2021;12:674192. https:\/\/doi.org\/10.3389\/fimmu.2021.674192.","journal-title":"Front Immunol"},{"issue":"1","key":"15795_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12282-016-0698-z","volume":"24","author":"S Burugu","year":"2017","unstructured":"Burugu S, Asleh-Aburaya K, Nielsen TO. Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication. Breast Cancer. 2017;24(1):3\u201315. https:\/\/doi.org\/10.1007\/s12282-016-0698-z.","journal-title":"Breast Cancer"},{"issue":"2","key":"15795_CR10","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3390\/cells10020223","volume":"10","author":"MV Dieci","year":"2021","unstructured":"Dieci MV, Miglietta F, Guarneri V. Immune infiltrates in breast cancer: recent updates and clinical implications. Cells. 2021;10(2):223. https:\/\/doi.org\/10.3390\/cells10020223.","journal-title":"Cells"},{"issue":"18","key":"15795_CR11","doi-asserted-by":"publisher","first-page":"4479","DOI":"10.3390\/cancers15184479","volume":"15","author":"G Angelico","year":"2023","unstructured":"Angelico G, Broggi G, Tinnirello G, et al. Tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer: a review of current evidence and prognostic implications. Cancers (Basel). 2023;15(18):4479. https:\/\/doi.org\/10.3390\/cancers15184479.","journal-title":"Cancers (Basel)"},{"key":"15795_CR12","doi-asserted-by":"publisher","first-page":"103280","DOI":"10.1016\/j.critrevonc.2021.103280","volume":"160","author":"R Torrisi","year":"2021","unstructured":"Torrisi R, Marrazzo E, Agostinetto E, et al. Neoadjuvant chemotherapy in hormone receptor-positive\/HER2-negative early breast cancer: when, why and what? Crit Rev Oncol Hematol. 2021;160:103280. https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103280.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"15795_CR13","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s10549-018-4801-3","volume":"170","author":"W Haque","year":"2018","unstructured":"Haque W, Verma V, Hatch S, et al. Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy. Breast Cancer Res Treat. 2018;170(3):559\u201367. https:\/\/doi.org\/10.1007\/s10549-018-4801-3.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"15795_CR14","doi-asserted-by":"publisher","first-page":"213","DOI":"10.5152\/ejbh.2020.5487","volume":"16","author":"R Omranipour","year":"2020","unstructured":"Omranipour R, Jalili R, Yazdankhahkenary A, et al. Evaluation of pathologic complete response to neoadjuvant chemotherapy in estrogen receptor-positive and HER2-negative breast cancer. Eur J Breast Health. 2020;16(3):213\u20138. https:\/\/doi.org\/10.5152\/ejbh.2020.5487.","journal-title":"Eur J Breast Health"},{"issue":"4","key":"15795_CR15","doi-asserted-by":"publisher","first-page":"356","DOI":"10.4274\/ejbh.galenos.2021.2021-4-8","volume":"17","author":"E Barbieri","year":"2021","unstructured":"Barbieri E, Gentile D, Bottini A, et al. Neo-adjuvant chemotherapy in luminal, node-positive breast cancer: characteristics, treatment and oncological outcomes. Eur J Breast Health. 2021;17(4):356\u201362. https:\/\/doi.org\/10.4274\/ejbh.galenos.2021.2021-4-8.","journal-title":"Eur J Breast Health"},{"key":"15795_CR16","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s13058-025-02150-2","volume":"27","author":"Y Qiu","year":"2025","unstructured":"Qiu Y, Zhang R, Liu S, et al. Dynamic tumor-infiltrating lymphocytes predicts survival in HR+\/HER2\u2009\u2013\u2009early breast cancer: a pre-to-post neoadjuvant chemotherapy study. Breast Cancer Res. 2025;27:205. https:\/\/doi.org\/10.1186\/s13058-025-02150-2.","journal-title":"Breast Cancer Res"},{"issue":"9","key":"15795_CR17","doi-asserted-by":"publisher","first-page":"e1466017","DOI":"10.1080\/2162402X.2018.1466017","volume":"7","author":"A Matikas","year":"2018","unstructured":"Matikas A, L\u00f6vrot J, Ramberg A, et al. Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor-positive, HER2-negative breast cancer. Oncoimmunology. 2018;7(9):e1466017. https:\/\/doi.org\/10.1080\/2162402X.2018.1466017.","journal-title":"Oncoimmunology"},{"key":"15795_CR18","doi-asserted-by":"publisher","first-page":"999843","DOI":"10.3389\/fonc.2022.999843","volume":"12","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Tzoras E, Matikas A, et al. Expression patterns and prognostic implications of tumor-infiltrating lymphocytes dynamics in early breast cancer patients receiving neoadjuvant therapy: a systematic review and meta-analysis. Front Oncol. 2022;12:999843. https:\/\/doi.org\/10.3389\/fonc.2022.999843.","journal-title":"Front Oncol"},{"issue":"1","key":"15795_CR19","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3892\/ol.2017.6144","volume":"14","author":"K Al Saleh","year":"2017","unstructured":"Al Saleh K, Abd El Aziz N, Ali A, et al. Predictive and prognostic significance of CD8\u2009+\u2009tumor-infiltrating lymphocytes in luminal B\/HER2-negative breast cancer treated with neoadjuvant chemotherapy. Oncol Lett. 2017;14(1):337\u201344. https:\/\/doi.org\/10.3892\/ol.2017.6144.","journal-title":"Oncol Lett"},{"key":"15795_CR20","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1186\/s12885-025-15022-x","volume":"25","author":"L Li","year":"2025","unstructured":"Li L, Yang P, Hong C, et al. Predictive value of tumor-infiltrating lymphocytes for neoadjuvant therapy response and prognosis in breast cancer: a multicenter retrospective study. BMC Cancer. 2025;25:1585. https:\/\/doi.org\/10.1186\/s12885-025-15022-x.","journal-title":"BMC Cancer"},{"key":"15795_CR21","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13058-017-0884-8","volume":"19","author":"V Pelekanou","year":"2017","unstructured":"Pelekanou V, Carvajal-Hausdorf D, Altan M, et al. Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer. Breast Cancer Res. 2017;19:91. https:\/\/doi.org\/10.1186\/s13058-017-0884-8.","journal-title":"Breast Cancer Res"},{"key":"15795_CR22","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.3390\/cancers15102846","volume":"15","author":"E Garc\u00eda-Torralba","year":"2023","unstructured":"Garc\u00eda-Torralba E, P\u00e9rez Ramos M, Ivars Rubio A, et al. Clinical meaning of stromal tumor infiltrating lymphocytes in early luminal B breast cancer. Cancers (Basel). 2023;15:2846. https:\/\/doi.org\/10.3390\/cancers15102846.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"15795_CR23","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/modpathol.2013.153","volume":"27","author":"L Feeley","year":"2014","unstructured":"Feeley L, Mulligan A, Pinnaduwage D, et al. Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information. Mod Pathol. 2014;27(4):554\u201361. https:\/\/doi.org\/10.1038\/modpathol.2013.153.","journal-title":"Mod Pathol"},{"issue":"4","key":"15795_CR24","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.21873\/anticanres.14142","volume":"40","author":"H Lee","year":"2020","unstructured":"Lee H, Lee M, Seo JH, et al. Changes in tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and clinical significance in triple-negative breast cancer. Anticancer Res. 2020;40(4):1883\u201390. https:\/\/doi.org\/10.21873\/anticanres.14142.","journal-title":"Anticancer Res"},{"key":"15795_CR25","doi-asserted-by":"publisher","first-page":"113399","DOI":"10.1016\/j.ejca.2023.113399","volume":"195","author":"F Miglietta","year":"2023","unstructured":"Miglietta F, Dieci MV, Giarratano T, et al. Association of tumor-infiltrating lymphocytes with recurrence score in hormone receptor-positive\/HER2-negative breast cancer. Eur J Cancer. 2023;195:113399. https:\/\/doi.org\/10.1016\/j.ejca.2023.113399.","journal-title":"Eur J Cancer"},{"issue":"1","key":"15795_CR26","doi-asserted-by":"publisher","first-page":"46","DOI":"10.14449\/jbd.2022.10.1.46","volume":"10","author":"S Lim","year":"2022","unstructured":"Lim S, Lee Y, Kim J, et al. Progesterone receptor expression as a prognostic factor in luminal B breast cancer. J Breast Dis. 2022;10(1):46\u201352. https:\/\/doi.org\/10.14449\/jbd.2022.10.1.46.","journal-title":"J Breast Dis"},{"issue":"4","key":"15795_CR27","doi-asserted-by":"publisher","first-page":"e313","DOI":"10.1093\/oncolo\/oyab063","volume":"27","author":"Y Ni","year":"2022","unstructured":"Ni Y, Tsang JY, Shao Y, et al. Combining analysis of tumor-infiltrating lymphocytes and PD-L1 refined the prognostication of breast cancer subtypes. Oncologist. 2022;27(4):e313\u201327. https:\/\/doi.org\/10.1093\/oncolo\/oyab063.","journal-title":"Oncologist"},{"issue":"7","key":"15795_CR28","first-page":"4648","volume":"14","author":"H Zhang","year":"2022","unstructured":"Zhang H, Zhang X, Jin L, Wang Z. The neoadjuvant chemotherapy responses and survival rates of patients with different molecular subtypes of breast cancer. Am J Transl Res. 2022;14(7):4648\u201356.","journal-title":"Am J Transl Res"},{"issue":"11","key":"15795_CR29","doi-asserted-by":"publisher","first-page":"e2442663","DOI":"10.1001\/jamanetworkopen.2024.42663","volume":"7","author":"DS Shin","year":"2024","unstructured":"Shin DS, Lee J, Kang E, et al. Age and late recurrence in young patients with ER-positive, ERBB2-negative breast cancer. JAMA Netw Open. 2024;7(11):e2442663. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.42663.","journal-title":"JAMA Netw Open"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15795-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15795-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15795-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T12:33:27Z","timestamp":1775565207000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15795-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15795"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15795-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"21 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Adiyaman University Ethics Committee (Date: 1\/11\/2025 No:10\/25). The requirement for informed consent was waived by the Ethics Committee due to the retrospective and anonymized nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patient data were anonymized and no identifying information is included in this manuscript. Therefore, consent for publication was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"440"}}